Conference Call │ FY/21 Results

Bad Homburg, 22 February 2022

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

2

Agenda

01

Key messages

02

03

04

Strategic update

Financial review

Outlook FY/22

FY/21

FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

3

Our Purpose and Mission

Ever better medicine for ever

more people

We improve people's lives by providing high

quality and affordable health care

FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

4

Key Messages

2021

Good close to the year; delivered on improved FY/21 guidance

Dividend to increase to €0.92 per share - scrip dividend proposed; choice to re-invest dividend into FRE

2022

Targets return to earnings

Continued progress

growth

back to normal operations

expected

Transformation program

Ongoing recovery of

Vision 2026 initiated for

business expected

continued success

Mid-term

Medium-term growth targets confirmed and specified

Strategic roadmap:

Significant value creation

expected based on

new strategic imperatives

FY/21 Results, 22 February 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 22 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2022 06:30:07 UTC.